- Home
- ARDX vs BTX Comparison
ARDX vs BTX Comparison
Compare ARDX & BTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARDX
- BTX
- Stock Information
- Founded
- ARDX 2007
- BTX N/A
- Country
- ARDX United States
- BTX United States
- Employees
- ARDX N/A
- BTX N/A
- Industry
- ARDX Biotechnology: Pharmaceutical Preparations
- BTX
- Sector
- ARDX Health Care
- BTX
- Exchange
- ARDX Nasdaq
- BTX Nasdaq
- Market Cap
- ARDX 882.9M
- BTX 854.3M
- IPO Year
- ARDX 2014
- BTX N/A
- Fundamental
- Price
- ARDX $6.55
- BTX $6.89
- Analyst Decision
- ARDX Strong Buy
- BTX
- Analyst Count
- ARDX 9
- BTX 0
- Target Price
- ARDX $10.50
- BTX N/A
- AVG Volume (30 Days)
- ARDX 3.2M
- BTX 734.4K
- Earning Date
- ARDX 10-30-2025
- BTX 11-01-2025
- Dividend Yield
- ARDX N/A
- BTX 14.63%
- EPS Growth
- ARDX N/A
- BTX N/A
- EPS
- ARDX N/A
- BTX N/A
- Revenue
- ARDX $386,146,000.00
- BTX N/A
- Revenue This Year
- ARDX $17.79
- BTX N/A
- Revenue Next Year
- ARDX $27.82
- BTX N/A
- P/E Ratio
- ARDX N/A
- BTX N/A
- Revenue Growth
- ARDX 83.88
- BTX N/A
- 52 Week Low
- ARDX $3.21
- BTX $5.10
- 52 Week High
- ARDX $7.18
- BTX $8.31
- Technical
- Relative Strength Index (RSI)
- ARDX 71.64
- BTX 36.13
- Support Level
- ARDX $6.47
- BTX $6.84
- Resistance Level
- ARDX $6.78
- BTX $7.16
- Average True Range (ATR)
- ARDX 0.19
- BTX 0.09
- MACD
- ARDX -0.05
- BTX -0.01
- Stochastic Oscillator
- ARDX 67.18
- BTX 14.49
About ARDX Ardelyx Inc.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
About BTX BlackRock Technology and Private Equity Term Trust Common Shares of Beneficial Interest
BlackRock Technology and Private Equity Term Trust objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation. The Trust will invest in equity securities issued by mid - and small capitalization companies that the Trust's adviser believes have above-average earnings growth potential.